Keywords
Inflammatory bowel disease
Ulcerative colitis
Crohn’s disease
Retrospective study
Submitted : 2023-02-27
Accepted : 2023-03-14
Published : 2023-03-29
Abstract
Background: Inflammatory bowel disease (IBD) has been linked to an increased risk of prostate cancer (PC) in numerous studies. However, the exact relationship between them remains conflicting. In this meta-analysis, we focus on determining the relationship between PC incidence and IBD. Methods: A comprehensive literature search was conducted up until January 2022, selecting 14 studies, comprising 127,323 subjects with IBD, at the beginning of the study, among which 61,985 were patients with ulcerative colitis (UC) and 37,802 were with Crohn’s disease (CD). The studies reported the differences between subjects with IBD and controls with regard to the incidence of PC. In order to investigate the relationship between IBD and the prevalence of PC, we estimated the odds ratio (OR) with 95% confidence intervals (CIs). Results: IBD significantly increased the incidence of PC (OR, 3.46; 95% CI, 1.40–8.54, P = 0.007) compared to controls. UC significantly increased the incidence of PC (OR, 1.43; 95% CI, 1.03–1.98, P = 0.03) compared to controls. Yet, no significant difference was observed between CD and controls in relation to PC incidence (OR, 0.89; 95% CI, 0.75–1.06, P = 0.18). Conclusion: IBD, particularly UC, may increase the risk of developing PC. This relationship prompts us to advocate for increased PC and IBD screening to reduce the risk for possible complications that could occur in these subjects.
References
Lakatos PL, 2009, Prevalence, Predictors, and Clinical Consequences of Medical Adherence in IBD: How to Improve It?. World Journal of Gastroenterology: WJG, 15(34): 4234.
Ng SC, Tang W, Ching JY, et al., 2013, Incidence and Phenotype of Inflammatory Bowel Disease Based on Results from the Asia-Pacific Crohn’s and Colitis Epidemiology Study. Gastroenterology, 145(1): 158–165.
Jess T, Horváth-Puhó E, Fallingborg J, et al., 2013, Cancer Risk in Inflammatory Bowel Disease According to Patient Phenotype and Treatment: A Danish Population-Based Cohort Study. American Journal of Gastroenterology, 108(12): 1869–1876.
Jess T, Gamborg M, Matzen P, et al., 2005, Increased Risk of Intestinal Cancer in Crohn’s Disease: A Meta-Analysis of Population-Based Cohort Studies. American Journal of Gastroenterology, 100(12): 2724–2729.
Sokol H, Beaugerie L, Maynadié M, et al., 2012, Excess Primary Intestinal Lymphoproliferative Disorders in Patients with Inflammatory Bowel Disease. IBDs, 18(11): 2063–2071.
Slesser A, Bhangu A, Bower M, et al., 2013, A Systematic Review of Anal Squamous Cell Carcinoma in Inflammatory Bowel Disease. Surgical Oncology, 22(4): 230–237.
Higgins JP, Thompson SG, Deeks JJ, et al., 2003, Measuring Inconsistency in Meta-Analyses. BMJ, 327(7414): 557–560.
Liberati A, Altman DG, Tetzlaff J, et al., 2009, The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. Journal of Clinical Epidemiology, 62(10): e1–e34.
Gupta A, Das A, Majumder K, et al., 2018, Obesity is Independently Associated with Increased Risk of Hepatocellular Cancer-Related Mortality. American Journal of Clinical Oncology, 41(9): 874–881.
Higgins JPT, Altman DG, Gøtzsche PC, et al., 2011, The Cochrane Collaboration’s Tool for Assessing Risk of Bias in Randomised Trials. BMJ, 343: d5928.
Sheikhbahaei S, Trahan TJ, Xiao J, et al., 2016, FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies. The Oncologist, 21(8): 931–939.
Bernstein CN, Blanchard JF, Kliewer E, et al., 2001, Cancer Risk in Patients with Inflammatory Bowel Disease: A Population?Based Study. Cancer, 91(4): 854–862.
Hemminki K, Li X, Sundquist J, et al., 2008, Cancer Risks in Ulcerative Colitis Patients. International Journal of Cancer, 123(6): 1417–1421.
Hemminki K, Li X, Sundquist J, et al., 2009, Cancer Risks in Crohn Disease Patients. Annals of Oncology, 20(3): 574–580.
Jussila A, Virta LJ, Pukkala E, et al., 2013, Malignancies in Patients with Inflammatory Bowel Disease: A Nationwide Register Study in Finland. Scandinavian Journal of Gastroenterology, 48(12): 1405–1413.
Wilson JC, Furlano RI, Jick SS, et al., 2016, A Population-Based Study Examining the Risk of Malignancy in Patients Diagnosed with Inflammatory Bowel Disease. Journal of Gastroenterology, 51(11): 1050–1062.
Mosher CA, 2016, Incidence of Colorectal Cancer and Extracolonic Cancers in Patients with Inflammatory Bowel. Pancreas, 54(8.5): 6.42.
Hovde Ø, Høivik M, Henriksen M, et al., 2017, Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-Up in the IBSEN Study. Journal of Crohn’s and Colitis, 11(5): 571–577.
Jung YS, Han M, Park S, et al., 2017, Cancer Risk in the Early Stages of Inflammatory Bowel Disease in Korean Patients: A Nationwide Population-Based Study. Journal of Crohn’s and Colitis, 11(8): 954–962.
So J, Tang W, Leung WK, et al., 2017, Cancer Risk in 2621 Chinese Patients with Inflammatory Bowel Disease: A Population-Based Cohort Study. IBDs, 23(11): 2061–2068.
Kundu S, Burns JA, Weiner AB, et al., 2018, IBD and the Risk of Prostate Cancer, American Society of Clinical Oncology.
Mosher CA, Brown GR, Weideman RA, et al., 2018, Incidence of Colorectal Cancer and Extracolonic Cancers in Veteran Patients with Inflammatory Bowel Disease. IBDs, 24(3): 617–623.
Burns JA, Weiner AB, Catalona WJ, et al., 2019, IBD and the Risk of Prostate Cancer. European Urology, 75(5): 846–852.
Taborelli M, Sozzi M, Del Zotto S, et al., 2020, Risk of Intestinal and Extra-Intestinal Cancers in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study in Northeastern Italy. PloS One, 15(6): e0235142.
Moher D, Liberati A, Tetzlaff J, et al., 2009, Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Plos Medicine, 6(7): e1000097.
Mottet N, De Santis M, Briers E, et al., 2018, Updated Guidelines for Metastatic Hormone-Sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard. Eur Urol, 73(3): 316–321.
Brawley OW, 2012, Prostate Cancer Epidemiology in the United States. World Journal of Urology, 30(2): 195–200.
Eaden J, Abrams K, Mayberry J, 2001, The Risk of Colorectal Cancer in Ulcerative Colitis: A Meta-Analysis. Gut, 48(4): 526–535.
Ogura Y, Bonen DK, Inohara N, et al., 2001, A Frameshift Mutation in NOD2 Associated with Susceptibility to Crohn’s Disease. Nature, 411(6837): 603–606.
Chen M, Yuan C, Xu T, 2020, An Increase in Prostate Cancer Diagnosis During Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Clinics and Research in Hepatology and Gastroenterology, 44(3): 302–309.
Farashi S, Kryza T, Clements J, et al., 2019, Post-GWAS in Prostate Cancer: From Genetic Association to Biological Contribution. Nature Reviews Cancer, 19(1): 46–59.
Rais R, Jiang W, Zhai H, et al., 2016, FOLH1/GCPII Is Elevated in IBD Patients, and Its Inhibition Ameliorates Murine IBD Abnormalities. JCI Insight, 1(12): e88634.
Coyle ME, Stupans I, Abdel-Nour K, et al., 2020, Acupuncture Versus Placebo Acupuncture for In Vitro Fertilisation: A Systematic Review and Meta-Analysis. Acupuncture in Medicine, 39(1): 20–29.